Comparative Pharmacology
Head-to-head clinical analysis: GANCICLOVIR SODIUM versus VITRASERT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GANCICLOVIR SODIUM versus VITRASERT.
GANCICLOVIR SODIUM vs VITRASERT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ganciclovir is a synthetic guanine derivative that inhibits viral DNA synthesis. It is phosphorylated to ganciclovir triphosphate by viral thymidine kinase (CMV UL97 gene product) and cellular kinases. Ganciclovir triphosphate competitively inhibits viral DNA polymerase (CMV UL54 gene product) and incorporates into viral DNA, causing chain termination.
Vitrasert (ganciclovir implant) releases ganciclovir, a nucleoside analog that inhibits cytomegalovirus (CMV) replication by competitively inhibiting viral DNA polymerase (UL54) after intracellular phosphorylation to ganciclovir triphosphate. This results in chain termination and viral DNA synthesis inhibition.
5 mg/kg IV every 12 hours for 14-21 days for induction; 5 mg/kg IV once daily or 6 mg/kg IV once daily 5 days per week for maintenance. Oral ganciclovir not available as sodium salt.
Intravitreal implant containing 0.59 mg fluocinolone acetonide; inserted into the vitreous cavity; releases drug over approximately 36 months; no systemic dosing.
None Documented
None Documented
Terminal half-life: 2.5-3.6 hours in normal renal function; prolonged in renal impairment (up to 30 hours in severe cases). Dosage adjustment required for CrCl <80 mL/min.
Terminal half-life of 2.8 hours following intravitreal injection; sustained local levels for 2-3 weeks.
Renal: >90% unchanged drug via glomerular filtration and tubular secretion. Biliary/fecal: <1%.
Primarily biliary/fecal (approximately 90%) with minimal renal excretion (<10% unchanged in urine).
Category D/X
Category C
Antiviral
Antiviral